How low can we go in community-acquired pneumonia therapy?

Affiliations

¹ Pulmonary and Critical Care Medicine, New York Presbyterian/Weill Cornell Medical Center, New York, NY 10065, USA. Electronic address: msn9004@med.cornell.edu.
² Division of Infectious Diseases, McMaster University, Hamilton, ON, Canada.

Comment

Michael S Niederman et al. Lancet. 2021.

. 2021 Mar 27;397(10280):1160-1161.

doi: 10.1016/S0140-6736(21)00627-9.

¹ Pulmonary and Critical Care Medicine, New York Presbyterian/Weill Cornell Medical Center, New York, NY 10065, USA. Electronic address: msn9004@med.cornell.edu.
² Division of Infectious Diseases, McMaster University, Hamilton, ON, Canada.

No abstract available

Comment on

Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A, Ropers J, Duran C, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Makhloufi S, Mellon G, de Lastours V, Bouchand F, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Renaud B, Perronne C, Claessens YE, Labarère J, Bedos JP, Aegerter P, Crémieux AC; Pneumonia Short Treatment (PTC) Study Group. Dinh A, et al. Lancet. 2021 Mar 27;397(10280):1195-1203. doi: 10.1016/S0140-6736(21)00313-5. Lancet. 2021. PMID: 33773631 Clinical Trial.